375 related articles for article (PubMed ID: 28031229)
1. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
Oh DY; Cham J; Zhang L; Fong G; Kwek SS; Klinger M; Faham M; Fong L
Cancer Res; 2017 Mar; 77(6):1322-1330. PubMed ID: 28031229
[TBL] [Abstract][Full Text] [Related]
2. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L
Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
[TBL] [Abstract][Full Text] [Related]
4. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
5. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
7. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T
BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719
[TBL] [Abstract][Full Text] [Related]
8. Prospects for the use of ipilimumab in treating advanced prostate cancer.
Wei XX; Fong L; Small EJ
Expert Opin Biol Ther; 2016; 16(3):421-32. PubMed ID: 26698365
[TBL] [Abstract][Full Text] [Related]
9. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis?
Nancey S; Boschetti G; Cotte E; Ruel K; Almeras T; Chauvenet M; Stroeymeyt K; Moussata D; Kaiserlian D; FlouriƩ B
Inflamm Bowel Dis; 2012 Aug; 18(8):E1598-600. PubMed ID: 22069060
[No Abstract] [Full Text] [Related]
10. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Jochems C; Tucker JA; Tsang KY; Madan RA; Dahut WL; Liewehr DJ; Steinberg SM; Gulley JL; Schlom J
Cancer Immunol Immunother; 2014 Apr; 63(4):407-18. PubMed ID: 24514956
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
Cha E; Small EJ
Cancer Med; 2013 Apr; 2(2):243-52. PubMed ID: 23634292
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
13. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.
Kwek SS; Dao V; Roy R; Hou Y; Alajajian D; Simko JP; Small EJ; Fong L
J Immunol; 2012 Oct; 189(7):3759-66. PubMed ID: 22956585
[TBL] [Abstract][Full Text] [Related]
14. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Cha E; Klinger M; Hou Y; Cummings C; Ribas A; Faham M; Fong L
Sci Transl Med; 2014 May; 6(238):238ra70. PubMed ID: 24871131
[TBL] [Abstract][Full Text] [Related]
15. CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.
Wang Z; Davies JD
Int Immunopharmacol; 2007 Feb; 7(2):249-65. PubMed ID: 17178393
[TBL] [Abstract][Full Text] [Related]
16. Neurological immune-related adverse events of ipilimumab.
Bot I; Blank CU; Boogerd W; Brandsma D
Pract Neurol; 2013 Aug; 13(4):278-80. PubMed ID: 23487828
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
18. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
20. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]